In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...

Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...

FRANKFURT, April 28 (Reuters) - Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss ...

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, ...

The SYNCHRONIZE-1 trial evaluated survodutide in non-diabetic adults with obesity or overweight with at least 1 weight-related complication.

A GLP-1/glucagon dual agonist induced up to 16.6% weight loss at 76 weeks for adults with overweight or obesity and without ...

While wholesale costs for glucagon skyrocketed over the past decade, out-of-pocket costs haven't increased by much, researchers reported. The cost of unmixed glucagon increased 192% from 2010 to 2020 ...

Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method for ...

Glucagon increases the production of glucose by increasing glycogenolysis and gluconeogenesis in the liver, and by reducing glycogenesis and glycolysis. The release of glucagon in response to food ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...

No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved ...